problems with strong selection bias in the current study due to the large number of T2 patients. Salvage surgery was safe and was able to improve the survival rate. This chemoradiation regimen was considered successful in preserving laryngeal function.
Introduction
Squamous cell carcinoma (SCC) of the hypopharynx carries one of the worst prognoses of all upper aerodigestive tract cancers, particularly for tumors arising in the pyriform sinus, the most frequent site of hypopharyngeal origin [1] . Extended radical surgery, such as total pharyngo-laryngectomy (TPL), followed by radiotherapy is considered to be the standard treatment. The use of combined chemoradiotherapy (CRT) in the treatment of advanced resectable diseases is known as the organ preservation approach [2] . The National Comprehensive Cancer Network (NCCN) guidelines (2014, version 2) state that CRT, or surgical treatment, or induction chemotherapy followed by CRT or surgery is recommended for patients with T2-3 hypopharyngeal tumors requiring pharyngectomy with total laryngectomy. These guidelines also state that surgical treatment is preferred for patients with T4a hypopharyngeal tumors [3] .
We applied weekly cisplatin chemotherapy with concurrent radiotherapy for patients with hypopharyngeal cancer, as the efficacy and feasibility of this regimen have been reported previously [4] . We then retrospectively evaluated the survival and laryngeal preservation rates to verify the effectiveness of this treatment for patients with pyriform sinus SCC.
Abstract
Background Pyriform sinus squamous cell carcinoma (SCC) has one of the worst prognoses of all upper aerodigestive tract cancers. Improving clinical outcomes for patients with hypopharyngeal SCC has been particularly challenging for head and neck surgeons and oncologists. Methods We investigated 30 patients with pyriform sinus SCC to verify the effectiveness of weekly cisplatin chemotherapy with concurrent radiotherapy. Cisplatin was administered at a dose of 40 mg/m 2 on weeks 1, 2, 3, 5, 6, and 7 during definitive radiotherapy with the aim of preserving the larynx. Results All 30 patients achieved definitive radiotherapy at a median dose of 70 Gy (range 64-70 Gy). Cisplatin was administrated concomitantly a median of five times (range 2-6 times). Persistent or recurrent primary disease was observed in four patients (13 %). Persistent or recurrent nodal metastasis was observed in five patients (17 %). Nine salvage surgeries were performed for eight patients, of whom seven survived without any evidence of disease. Post-operative complications were observed in two patients (22 %). The 5-year overall survival and locoregional control rates were 87 and 96 %, respectively. The 5-year laryngeal preservation rate was 74 %. Conclusions The regimen of weekly cisplatin CRT may be effective for pyriform sinus SCC; however, there were
Materials and methods

Patient eligibility
Patients with resectable pyriform sinus SCC who underwent weekly cisplatin CRT between August 2006 and January 2013 in our institution were regarded as eligible.
Cases without any invasion to the prevertebral or deep cervical muscle or the carotid artery were defined as resectable cases.
An Eastern Cooperative Oncology Group performance status of 0-1 was required in addition to the following criteria: a white cell count of at least 4000/mm 3 , a platelet count of at least 100,000/mm 3 , a hemoglobin concentration of at least 9.5 g/dL, serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase levels of less than twice the upper limit of the normal range, a total bilirubin concentration of <2.0 mg/dL, a serum creatinine concentration of <1.5 g/dL, a blood urea nitrogen concentration of <25 mg/dL, and a creatinine clearance of >60 mL/min.
Approval for this study was obtained from the institutional review board at Hokkaido University. Completion of the survey was regarded as implied consent for participation.
Chemotherapy and concurrent radiotherapy
Cisplatin was administered at a dose of 40 mg/m 2 on weeks 1, 2, 3, 5, 6, and 7 of the radiotherapy. Patients received prophylactic hydration and 5HT 3 antagonists plus dexamethasone and/or neurokinin-1 receptor antagonist for anti-emetic prophylaxis. The intended maximum dose of cisplatin was 240 mg/m 2 . The cisplatin dose was modified on a case-by-case basis according to the level of adverse events.
The irradiation plan was 40 Gy in 20 fractions of 2 Gy over 4 weeks for the primary site and all nodal areas, immediately followed by a boost of 30 Gy in 15 fractions to the primary cancer and metastatic nodal area over an additional 3 weeks (total dose, 70 Gy).
Post-treatment evaluation
Initial post-treatment evaluation was performed within 1 month after the completion of initial treatment using laryngeal endoscopy. Computed tomography (CT) and/or magnetic resonance (MR) imaging were performed within 2 months after the completion of treatment. If persistent primary disease was observed, biopsy was attempted and salvage surgery was indicated by the presence of viable tumor cells. If persistent regional disease was observed, salvage neck dissection was indicated.
Patients were usually monitored monthly for recurrence in the first year, every couple of months in the second year, and every 6 or 12 months thereafter until death or data censoring. CT scans or MR imaging were routinely performed once every 3 months in the first year, and every 6 or 12 months thereafter. If recurrent primary disease was suspected, biopsy was attempted and, again, salvage surgery was indicated by the presence of tumor cells. If recurrent regional disease was observed, salvage neck dissection was indicated.
Salvage surgery
Salvage surgery was indicated for patients with recurrent primary disease. Salvage neck dissection was performed for patients with recurrent regional disease. Level II, III, or IV lymph nodes on the involved side were dissected as a rule, with level I or V lymph nodes also dissected if involved.
Statistics
We defined cases receiving more than 200 mg/m 2 of total cisplatin during CRT as completed, with the completion rate calculated accordingly.
Toxicities during CRT and surgical complications were graded using the Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0. Post-operative complications evaluated as grade 3 or 4 were recorded according to NCI-CTCAE Version 4.0, and the complication rate was calculated.
The Kaplan-Meier method was used for the calculation of survival and control rates using JMP 10.0.0 statistical software (SAS Institute, Cary, NC, USA). The time of interest was the period from the start of treatment to death or failure. The Kaplan-Meier method was also applied to calculate the laryngeal preservation rate. The time of interest was the period from the start of treatment to death or surgery with total laryngectomy.
Results
Patient characteristics
We treated 40 patients with resectable pyriform sinus SCC by weekly cisplatin CRT. Of these, 10 patients undergoing induction chemotherapy followed by weekly cisplatin CRT were excluded. The remaining 30 patients were eligible for this study. Table 1 shows the detailed demographics of the 30 patients enrolled in this study. None of the 30 patients showed any invasion to the prevertebral or deep cervical muscle or the carotid artery and, therefore, all 30 were thought to be resectable cases. The observation period for survivals ranged from 8.3 to 93.7 months (median 58 months).
Chemoradiotherapy and treatment compliance
All 30 patients achieved definitive radiotherapy at a median dose of 70 Gy (range 64-70 Gy). One patient developed aspiration pneumonia (Grade 3) after an irradiation dose of 64 Gy, and radiation therapy was subsequently discontinued. Cisplatin was administrated concomitantly a median of five times (range 2-6 times). Thirty-five patients (87.5 %) achieved a total dose of more than 200 mg/m 2 of cisplatin during CRT. One patient developed renal failure after cisplatin was administered twice, and chemotherapy was therefore discontinued. Chemotherapy was also discontinued in one patient after three doses of cisplatin due to severe mucositis (Grade 3), as well as in two patients after four doses of cisplatin due to hypokalemia (Grade 3) and dermatitis (Grade 3), respectively. A summary of these patients who did not complete the definitive radiotherapy or chemotherapy is shown in Table 2 . Table 3 shows the details of acute toxicity during CRT. Late complications were observed in one patient (3 %). This patient with severe stenosis of the pharynx required TPL and free jejunal reconstruction 10 months after the completion of CRT.
Patient outcomes and salvage surgery
Persistent or recurrent primary disease was observed in four patients (13 %) after weekly cisplatin CRT. These four patients underwent salvage surgery with total laryngectomy a median of 25.4 months (range 6.6-54.7 months) after the completion of weekly cisplatin CRT. Of these four patients undergoing salvage surgery with total laryngectomy, three survived without any evidence of disease. The remaining patient died of primary disease at 2 months after the salvage surgery.
Persistent or recurrent nodal metastasis was observed in five patients (17 %) after weekly cisplatin CRT. These five patients underwent salvage neck dissection. All five patients survived without any evidence of disease.
Post-operative complications were observed in two of the nine patients (22 %) undergoing salvage surgery. Fistula formation (Grade 3) was observed in one patient after pharyngectomy with total laryngectomy. One case of neck numbness (Grade 3) was also observed after salvage neck dissection.
Distant metastasis was observed in one patient at 23.1 months after the completion of weekly cisplatin CRT. This patient died from lung metastasis at 32.8 months after the completion of weekly cisplatin CRT. 
Overall survival and laryngeal preservation survival rates
In all participants, the 5-year overall survival and locoregional control rates were 87 and 96 %, respectively (Fig. 1) . The 5-year laryngeal preservation rate was 74 % for all participants. Figure 2 shows the laryngeal preservation curve. The 5-year overall survival rates of patients with T1, T2, T3, and T4a tumors were 100, 88, 83, and 100 %, respectively. Those of patients with N0, N1, N2a-c, and N3 tumors were 81, 100, 89, and 100 %, respectively. Further, the 5-year laryngeal preservation rates of patients with T1, T2, T3, and T4a tumors were 0, 76, 83, and 100 %, respectively, while those of patients with N0, N1, N2a-c, and N3 tumors were 73, 100, 65, and 100 %, respectively.
Discussion
Hypopharyngeal SCC has one of the worst prognoses among malignant neoplasms, with the 5-year overall survival rate reported to be 35 % with intensive surgical treatment, such as TPL [5] . Therefore, improving clinical outcomes for patients with hypopharyngeal SCC has been particularly challenging for head and neck surgeons and oncologists. CRT has been used for patients with advanced hypopharyngeal cancer with the aim of preserving the larynx. Although tri-weekly high-dose (100 mg/m 2 ) cisplatin (three cycles) and radiotherapy has been considered a standard regimen, this protocol is associated with significant acute and late toxicities [6] [7] [8] [9] . Furthermore, the completion rate for this regimen is relatively poor [6, 7] . Therefore, weekly cisplatin at a dose of 40 mg/m 2 has been used at our institution since 2006, and we have also applied this treatment for patients with advanced pyriform sinus SCC. The favorable outcomes of this protocol were clarified in the current study. For comparison, we also investigated the overall survival of 23 patients with advanced pyriform sinus SCC undergoing surgical treatment at the same time in our institution. The 5-year overall survival and locoregional control rates of the surgical treatment group were 50.4 and 75.7 %, respectively. The number of patients with T2, 3, and 4a tumors in the surgical treatment group was 6, 4, and 13, respectively. The median age of the surgical treatment group was 72 years, which was older than the median age (62 years) of the CRT group. Due to the marked inequality between the CRT group and the surgical treatment group, it was difficult to compare the outcomes between two groups. We recognize that there was a strong tendency for the surgical treatment to be indicated for more advanced primary disease and older patients in comparison to those receiving CRT. Therefore, the effectiveness of weekly cisplatin CRT remains to be confirmed on larger populations of patients with more advanced primary tumors, and further studies are needed to prove clarify this efficacy.
Long before the year 2000, various CRT regimens were investigated for patients with hypopharyngeal cancer with the aim of preserving the larynx. Yoon et al. [10] reported the outcomes of high-dose cisplatin (100 mg/m 2 ) CRT for 28 patients with locally advanced hypopharyngeal cancer. The 3-year overall survival and locoregional control rates were 54 and 52 %, respectively. Prades et al. [11] presented the outcomes of carboplatin CRT for 46 patients with pyriform sinus carcinoma, with a 2-year overall survival rate of 53-58 %. Tai et al. [12] investigated 42 patients with advanced hypopharyngeal cancer who were treated by CRT consisting of cisplatin and 5-FU with and without induction chemotherapy. The 3-year overall survival rate was reported to be 50 %. A comparison with these previous reports shows that the 5-year overall survival and locoregional control rates (78.8 and 89.2 %) in the current study were superior to those of other regimens. We speculated that the advantage of the weekly cisplatin regimen is that it enables an adequate total dose of cisplatin to be administered during concurrent radiotherapy. It was confirmed that over 80 % of all participants achieved this regimen, with this high completion rate considered to lead to improved outcomes.
In the current study, local or regional recurrence was observed in eight patients, of whom all eight underwent salvage surgery. Seven patients (87.5 %) survived after salvage surgery without any evidence of disease. The postoperative complication rate (22 %) was also acceptable. These reasonable salvage and complication rates encouraged us to perform salvage surgery after weekly cisplatin CRT. We considered that salvage surgery could contribute to the improvement of overall survival and locoregional control for patients with persistent or recurrent locoregional disease.
The favorable laryngeal preservation rate (74 %) achieved in our current study confirmed that weekly cisplatin chemotherapy with concurrent radiotherapy was effective in preserving laryngeal function.
Conclusions
The regimen of weekly cisplatin CRT may be effective for pyriform sinus SCC; however, there were problems with strong selection bias in the current study due to the large number of T2 patients. The high completion rate of weekly cisplatin CRT together with appropriate salvage surgery could contribute to favorable outcomes. Further, we confirmed the safety and efficacy of salvage surgery following CRT. These combined therapies could improve the overall survival for patients with pyriform sinus SCC.
